# Finerenone and Cardiac Remodeling

Study · id `cardio:ct-nct07270367` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07270367](<https://clinicaltrials.gov/study/NCT07270367>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07270367

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 156 participants.

## Technical summary

Registry record NCT07270367. Randomized; quadruple masking; primary purpose treatment. Start 2025-12 (anticipated); primary completion 2030-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 156 participants (planned count; ClinicalTrials.gov record NCT07270367, source copy `cardio:ctgov-nct07270367-2025-12-08`, retrieved 2026-10-26)
- Planned start: 2025-12 (anticipated) (ClinicalTrials.gov record NCT07270367, source copy `cardio:ctgov-nct07270367-2025-12-08`, retrieved 2026-10-26)
- Primary completion: 2030-12 (anticipated) (ClinicalTrials.gov record NCT07270367, source copy `cardio:ctgov-nct07270367-2025-12-08`, retrieved 2026-10-26)
- Completion: 2030-12 (anticipated) (ClinicalTrials.gov record NCT07270367, source copy `cardio:ctgov-nct07270367-2025-12-08`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT07270367, source copy `cardio:ctgov-nct07270367-2025-12-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07270367-2025-12-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Finerenone and Cardiac Remodeling
- Acronym: FINE-MECH
- Condition: Heart Failure
- Intervention (Drug): Finerenone
- Intervention (Drug): Placebo
- Lead sponsor: Subodh Verma
- Lead sponsor class: OTHER
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Finerenone (`cardio:finerenone`)
- Registry intervention is a member of this class by a sourced record link: Mineralocorticoid receptor antagonists (drug class) (`cardio:mineralocorticoid-receptor-antagonists`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

## Provenance

Content hash: ef21b8c9e3f36b46da1ca2be5200d07073e4b5f0a2c2128e60a1d3565adce9e6
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
